Breaking Finance News

Clearside Biomedical Inc (NASDAQ:CLSD) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Clearside Biomedical Inc(NASDAQ:CLSD) to Hold in a statement released on 9/19/2016.

Just yesterday Clearside Biomedical Inc (NASDAQ:CLSD) traded 24.73% higher at $10.44. CLSD’s 50-day moving average is $7.38 and its two hundred day moving average is $7.07. With the last close up 47.67% relative to the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. 171,435 shares of Clearside Biomedical Inc exchanged hands, up from ann average volume of 32,869.

See Graph Below:

Clearside Biomedical Inc (NASDAQ:CLSD)

With a market cap of $0.0, Clearside Biomedical Inc has a PE of 0 with a one-year low of $5.65 and a 52 week high of $11.31.

Also covering Clearside Biomedical Inc’s stock price target, a total of 3 brokers have issued a ratings update on the company. The average target stock price is $19.00 with 0 rating the company a strong buy, 0 rating the stock a buy, 0 firms rating the stock a hold, 0 rating the stock to underperform, and finally 0 analystsrating the stock as sell.

More About Clearside Biomedical Inc (NASDAQ:CLSD)

Clearside Biomedical, Inc. is a late-stage clinical biopharmaceutical company. The Company is developing drug therapies to treat blinding diseases of the eye. The Company’s product candidates are focused on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space (SCS) adjacent to the choroid, using its SCS Microinjector. With the SCS injection, its product candidates are directly administered to the retina and choroid. Its product candidates are CLS-1001, CLS-1003 and CLS-1002. CLS-1001 and CLS-1003 are based on commonly used ophthalmic drugs. Its CLS-1001 program is being developed for the treatment of macular edema associated with non-infectious uveitis. CLS-1001 consists of an SCS injection of Zuprata, its preservative-free formulation of the corticosteroid triamcinolone acetonide (TA), and specifically designed to be administered through its SCS Microinjector.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *